标题
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 7, Pages E748-E757
出版商
Proceedings of the National Academy of Sciences
发表日期
2014-02-04
DOI
10.1073/pnas.1320956111
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
- (2012) Michael S. Glickman et al. CELL
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
- (2012) Oliver Gautschi et al. Journal of Thoracic Oncology
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
- (2012) Cole Trapnell et al. Nature Protocols
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TopHat: discovering splice junctions with RNA-Seq
- (2009) Cole Trapnell et al. BIOINFORMATICS
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
- The cancer biomarker problem
- (2008) Charles L. Sawyers NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation